|Bid||72.85 x 1400|
|Ask||76.32 x 1400|
|Day's range||75.03 - 77.63|
|52-week range||61.91 - 85.97|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||18.02|
|Earnings date||01 Aug 2022 - 05 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||91.86|
Sometimes, the smart-money move is to dive in on a dip and leave your stocks alone for a decade or more.
MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.